Alendronate + Exercise for Osteoporosis

(BEACON Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen by Kristen M Beavers, PhD, MPH, RD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: Wake Forest University Health Sciences

Must not be taking: Oral steroids, Insulin, Biotin, others

Disqualifiers: Osteoporosis, Uncontrolled diabetes, Cancer, others

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 6 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on certain medications like oral steroids, diabetes prescriptions, or osteoporosis medications, you may not be eligible to participate.

What data supports the effectiveness of the drug Alendronate for osteoporosis?

Research shows that branded Alendronate (Fosamax) significantly increases bone mineral density (BMD) in patients with postmenopausal osteoporosis, which helps strengthen bones and reduce the risk of fractures. Additionally, studies indicate that Alendronate is effective in reducing the incidence of fractures, making it a reliable treatment for osteoporosis. ^{1 2 3 4 5}

Is the combination of Alendronate and exercise safe for treating osteoporosis?

Alendronate, a type of bisphosphonate, is generally safe for most people, but it can cause side effects like stomach discomfort, flu-like symptoms, and rarely, jaw bone problems or unusual fractures. It's important to follow dosing instructions carefully to avoid issues like esophageal damage. ^{6 7 8 9 10}

How does the drug Alendronate differ from other osteoporosis treatments?

Alendronate is unique because it is an aminobisphosphonate that specifically inhibits bone turnover by suppressing osteoclast activity, which helps prevent bone loss without increasing the risk of osteomalacia (softening of the bones). It is highly effective in increasing bone mass and reducing fracture risk in postmenopausal women, and it is typically taken once daily on an empty stomach to improve absorption. ^{3 11 12 13 14}

Research Team

Kristen M Beavers, PhD, MPH, RD

Principal Investigator

Wake Forest University Health Sciences

Eligibility Criteria

Adults with a BMI over 30, or over 25 with a risk factor, who have low bone mass but not full-blown osteoporosis can join. They must be able to walk without assistance, get regular dental care, and commit to the study visits for up to two years.

Inclusion Criteria

I get dental check-ups at least once a year.

Community-dwelling

My bone density test shows I have low bone mass.

Exclusion Criteria

I need a quad cane or walker to move around.

My blood pressure is not higher than 180/110 mmHg.

My weight is under 450 lbs.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants undergo a 12-month intervention of resistance training plus bone-loading exercises and bisphosphonate use, or placebo, to assess effects on bone mineral density.

12 months

Up to 9 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments of bone mineral density and other bone quality measures.

12 months

Regular assessments at baseline, month 6, and month 12

Treatment Details

Interventions

• Bisphosphonate (Bisphosphonate)
• Placebo (Other)
• Resistance Training/Bone-Loading Exercise (Behavioral Intervention)

Trial Overview The trial is testing if bisphosphonates (a type of medication) and resistance training exercises can help minimize bone loss during weight loss in older adults. Participants will also explore the effects of caloric restriction on bone health.

Participant Groups

Group I: Resistance Training (RT) + Bisphosphonate (BIS) Experimental Treatment 2 Interventions

Progressive Resistance Training (RT) and Bone-Loading Exercise + 70 mg/weekly dose alendronate

Group II: No RT + BIS Experimental Treatment 1 Intervention

No Resistance Training + 70 mg/weekly dose alendronate

Group III: No RT + Placebo (PL) Active Control 1 Intervention

No Resistance Training + Weekly Placebo

Group IV: RT + PL Active Control 2 Interventions

Progressive RT and Bone-Loading Exercise + Weekly Placebo

Bisphosphonate is already approved in Canada, Japan, China, Switzerland for the following indications:

Approved in Canada as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Approved in Japan as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Approved in China as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Approved in Switzerland as Bisphosphonates for:

• Osteoporosis
• Paget's disease
• High calcium levels in cancer patients
• Bone metastases

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials

1,432

Recruited

2,506,000+

Dr. L. Ebony Boulware

Wake Forest University Health Sciences

Chief Medical Officer since 2022

MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health

Dr. Julie Ann Freischlag

Wake Forest University Health Sciences

Chief Executive Officer since 2020

BS from University of Illinois, MD from Rush University

National Institute on Aging (NIA)

Collaborator

Trials

1,841

Recruited

28,150,000+

Dr. Richard J. Hodes

National Institute on Aging (NIA)

Chief Executive Officer since 1993

MD from Harvard Medical School

Dr. Marie Bernard

National Institute on Aging (NIA)

Chief Medical Officer

MD from Harvard Medical School

Findings from Research

A study involving 32 postmenopausal women confirmed that a new intramuscular clodronate formulation (200 mg every two weeks) is bioequivalent to the standard formulation (100 mg weekly), meaning they work similarly in the body.

Both formulations were well-tolerated, with minimal side effects, suggesting that the less frequent dosing of the 200 mg formulation could improve patient adherence to osteoporosis treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients. Radicioni, M., Cremonesi, G., Baraldi, E., et al.[2013]

The most important outcome for osteoporosis therapies is the reduction in fracture risk, rather than just changes in bone mineral density, highlighting a shift in focus for treatment effectiveness.

Among the bisphosphonates, alendronate and risedronate have shown the strongest evidence for reducing both vertebral and non-vertebral fractures, making them key options in osteoporosis management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability. Masud, T., Giannini, S.[2019]

In a study of 186 women with postmenopausal osteoporosis, generic alendronate showed significantly lower increases in bone mineral density (BMD) compared to branded alendronate (Fosamax®) and branded risedronate (Actonel®) after one year, suggesting that the generic may be less effective.

Patients taking generic alendronate also had lower treatment persistence (68%) compared to those on branded medications (84% for Fosamax® and 94% for Actonel®), which may be linked to a higher incidence of gastrointestinal side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Ringe, JD., Möller, G.[2021]

Oral bisphosphonates, commonly used for osteoporosis, can cause various adverse events including gastrointestinal issues, musculoskeletal pain, and osteonecrosis of the jaw, while intravenous bisphosphonates are linked to similar issues but with added risks of renal toxicity.

The severity and frequency of adverse events from bisphosphonates are often related to the dosage and potency of the medication, highlighting the need for careful management in their use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bisphosphonate-associated adverse events. Papapetrou, PD.[2022]

Clodronate, a bisphosphonate, has been shown to significantly reduce the incidence of vertebral fractures after 4 years of treatment, particularly in patients at higher fracture risk, making it an effective option for osteoporosis and related bone conditions.

The drug is safe and well-tolerated, with flexible dosing strategies that can be tailored to individual fracture risk and pain severity, promoting better adherence to treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clodronate news of efficacy in osteoporosis. Nardi, A., Ventura, L., Cozzi, L., et al.[2020]

In a study of 74 asthmatic patients on long-term corticosteroid therapy, clodronate significantly increased bone mineral density (BMD) in the lumbar spine and femoral neck, particularly at higher doses of 1600 mg and 2400 mg per day.

Clodronate was effective in preventing bone loss, but the 2400 mg dose was associated with gastric irritation as a common side effect, highlighting the need to balance efficacy with tolerability.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Herrala, J., Puolijoki, H., Liippo, K., et al.[2019]

Bisphosphonates, such as risedronate, have shown strong efficacy in preventing bone loss in postmenopausal women, with a study indicating that a daily dose of 5 mg completely prevented bone loss compared to a placebo.

New bisphosphonates like ibandronate and zoledronate are being developed with promising results, including significant increases in spinal bone mass and normalization of serum alkaline phosphatase in over 70% of patients, providing alternative treatment options for those intolerant to oral bisphosphonates.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New bisphosphonates in the treatment of bone diseases. Gatti, D., Adami, S.[2022]

Alendronate is an effective treatment for osteoporosis in postmenopausal women, significantly reducing the risk of vertebral and nonvertebral fractures, as shown in large randomized controlled trials lasting up to 3 years.

The drug works by inhibiting osteoclast activity, which helps prevent bone loss without increasing the risk of osteomalacia, making it a safe option for increasing bone mass in women with osteoporosis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Drug clinics. The drug of the month. Alendronate (Fosamax)]. Scheen, AJ.[2015]

References

1. Germany pubmed.ncbi.nlm.nih.gov

Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients. [2013]

2. Germany pubmed.ncbi.nlm.nih.gov

Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability. [2019]

3. Germany pubmed.ncbi.nlm.nih.gov

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. [2021]

4. England pubmed.ncbi.nlm.nih.gov

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. [2019]

6. Switzerland pubmed.ncbi.nlm.nih.gov

Bisphosphonate-associated adverse events. [2022]

7. Ireland pubmed.ncbi.nlm.nih.gov

Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. [2019]

8. United States pubmed.ncbi.nlm.nih.gov

Adverse effects of bisphosphonates. [2022]

9. Italy pubmed.ncbi.nlm.nih.gov

Bisphosphonates and osteoporosis treatment in Italy. [2019]

10. United States pubmed.ncbi.nlm.nih.gov

Alendronate: a bisphosphonate for treatment of osteoporosis. [2013]

11. Italy pubmed.ncbi.nlm.nih.gov

Clodronate news of efficacy in osteoporosis. [2020]

12. United States pubmed.ncbi.nlm.nih.gov

Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. [2019]

13. New Zealand pubmed.ncbi.nlm.nih.gov

New bisphosphonates in the treatment of bone diseases. [2022]

14. Belgium pubmed.ncbi.nlm.nih.gov

[Drug clinics. The drug of the month. Alendronate (Fosamax)]. [2015]